1h Free Analyst Time
The antibody drug conjugates market is forecasted to grow by USD 9.95 bn during 2023-2028, accelerating at a CAGR of 15.06% during the forecast period. The report on the antibody drug conjugates market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by growing prevalence of cancer and other diseases, technological advancements in ADC development, and increasing investments in pharmaceutical research and development.
The antibody drug conjugates market is segmented as below:
By Application
- Breast cancer
- Blood cancer
- Others
By Technology
- Cleavable linker
- Non-cleavable linker
- Linkerless
By Geography
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the antibody drug conjugates market covers the following areas:
- Antibody drug conjugates market sizing
- Antibody drug conjugates market forecast
- Antibody drug conjugates market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Application
7 Market Segmentation by Technology
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
List of Exhibits
Executive Summary
The publisher recognizes the following companies as the key players in the global antibody drug conjugates market: AbbVie Inc., Adcendo ApS, Araris Biotech AG, Astellas Pharma Inc., AstraZeneca Plc, Daiichi Sankyo Co. Ltd., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., ImmunoGen Inc., Merck KGaA, Mersana Therapeutics Inc., Mythic Therapeutics, Pfizer Inc., Piramal Enterprises Ltd., PPF Group, Regeneron Pharmaceuticals Inc., Seagen Inc., Syngene International Ltd., Takeda Pharmaceutical Co. Ltd., and ADC Therapeutics SA.Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is increasing adoption and development of targeted therapies.'
According to the report, one of the major drivers for this market is the growing prevalence of cancer and other diseases.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc.
- Adcendo ApS
- Araris Biotech AG
- Astellas Pharma Inc.
- AstraZeneca Plc
- Daiichi Sankyo Co. Ltd.
- F. Hoffmann La Roche Ltd.
- Gilead Sciences Inc.
- ImmunoGen Inc.
- Merck KGaA
- Mersana Therapeutics Inc.
- Mythic Therapeutics
- Pfizer Inc.
- Piramal Enterprises Ltd.
- PPF Group
- Regeneron Pharmaceuticals Inc.
- Seagen Inc.
- Syngene International Ltd.
- Takeda Pharmaceutical Co. Ltd.
- ADC Therapeutics SA